Shares of Indivior PLC (NASDAQ: INDV), a global pharmaceutical company specializing in substance use disorders, plummeted over 23% in the pre-market session on Thursday.
The sharp decline came after the company issued its guidance for fiscal year 2025, which was weaker than expected. According to the guidance, Indivior anticipates net revenue of $955 million to $1.025 billion for FY 2025, representing a 17% decrease at the midpoint compared to FY 2024.
Specifically, the company expects its SUBLOCADE net revenue to be in the range of $725 million to $765 million, which is relatively flat compared to FY 2024. However, the guidance suggests an accelerated decline in net revenue from SUBOXONE Film due to increased generic competition and the potential impact from a fifth buprenorphine/naloxone sublingual film generic entering the U.S. market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.